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Abstract
Background—Invasive lobular breast tumors display unique reproductive risk factor profiles. 
Lobular tumors are predominantly Luminal A subtype and it is unclear whether reported risk 
factor associations are independent of molecular subtype.
Methods—Polytomous logistic regression was used to estimate odds ratios (ORs) and 95% 
confidence intervals (95% CIs) for the associations between risk factors and histologic subtype 
[ductal (n=2,856), lobular (n=326), and mixed ductal-lobular (n=473)] in the Carolina Breast 
Cancer Study (1993–2013). Three-marker immunohistochemical clinical subtypes were defined as 
Luminal A (ER+ or PR+/HER2−), Luminal B (ER+ or PR+/HER2+), Triple Negative (ER−/PR−/
HER2−), and HER2+ (ER−/PR−/HER2+).
Results—In case-case analyses compared to ductal, lobular tumors were significantly associated 
with lactation duration >12 months [OR 1.86, 95% CI (1.33–2.60)], age at first birth ≥26 years 
[OR: 1.35, 95% CI: (1.03–1.78)], and current oral contraceptive use [OR: 1.86, 95% CI: (1.08–
3.20)]. Differences in risk factor associations between ductal and lobular tumors persisted after 
restricting to Luminal A subtype.
Conclusions—Lobular tumors were associated with older age at first birth, increased lactation 
duration, and current oral contraceptive use. Etiologic heterogeneity by histology persisted after 
restricting to Luminal A subtype, suggesting both tumor histology and intrinsic subtype play 
integral parts in breast cancer risk.
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The intrinsic breast cancer subtypes, including Luminal A, Luminal B, HER2-enriched, and 
Basal-like cancers, show distinct risk factor profiles and are hypothesized to be independent 
diseases within the breast [1, 2]. Ductal histologic subtype, diagnosed in up to 80% of 
invasive breast tumors [3–5], are approximately 50% Luminal A intrinsic subtype. While 
Basal-like and HER2-enriched intrinsic subtype tumors represent a minority of breast 
tumors, up to 20% and 10% of tumors, respectively [6, 7], the vast majority of Basal-like 
and HER2-enriched tumors are ductal histologic subtype and are rarely lobular or mixed 
ductal/lobular histologic subtypes [7–17]. Lobular and mixed ductal-lobular breast cancers, 
diagnosed in up to 15% of cases each [3–5], tend to be 80–90% Luminal A intrinsic subtype 
[3–5, 7–17]. Thus, there are strong associations between histologic and intrinsic subtype.
Previous studies of etiologic heterogeneity according to histology have suggested that 
lobular disease is more strongly associated with a number of reproductive risk factors and 
hormone-modulating exposures including younger age at menarche [18–22], older age at 
menopause [19, 22, 23], premenopausal status [23–25], combined estrogen and progesterone 
(E+P) hormone therapy (HT) use [26–29], and later age at first birth [18–22, 26, 28, 30]. 
The strongest differences in association for reproductive risk factors and lobular disease have 
been observed for combined hormone therapy use (odds ratios for current E+P HT use vs 
never range from 2.1–2.3 for lobular and 1.1–1.8 for ductal [27, 29]) and older age at first 
birth (case-control odds ratios for >30 vs ≤19 years of age range from 1.8–2.4 for lobular 
disease and 1.1–1.6 for ductal disease) [18–22, 26, 28, 30]. However, it is unclear if the 
observed associations depend on intrinsic breast cancer subtypes, which also have unique 
reproductive risk factor profiles [6, 7]. We sought to disentangle the associations between 
reproductive breast cancer risk factors and breast cancer subtype, considering both histology 
and Luminal A subtype in the Carolina Breast Cancer Study Phases 1–3 (1993–2013).
METHODS
Study population
The present analysis includes 3,655 cases of invasive breast cancer from the Carolina Breast 
Cancer Study (CBCS) Phases 1–3 (1993–2013). The CBCS is a population-based study 
among black and non-black women, initiated in 1993, that recruited participants from 24 
(CBCS 1–2) to 44 (CBCS 3) of the 100 North Carolina counties [31]. CBCS oversampled 
women less than 50 years of age and black women [9, 32].
For CBCS1–3, case eligibility criteria included: women with a first diagnosis of breast 
cancer [invasive or in situ (CBCS2 only)], aged 20–74 years at diagnosis, and residence in 
specified counties. Cases were enrolled following rapid case ascertainment from the NC 
Central Cancer Registry and controls (CBCS1–2) were identified using DMV and Medicare 
lists. Controls were frequency matched to cases by race and five-year age-group. All 
participants provided informed consent for study enrollment and cases granted access to 
tumor tissue blocks/slides and medical records from treatment centers. Self-report, risk 
factor data was collected during in-person interviews by a trained study nurse. Cases eligible 
for this analysis had invasive tumor tissue available for centralized pathology review and 
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were classified as ductal (n=2,856), lobular (n=326), or mixed ductal/lobular (n=473) 
(henceforth referred to as mixed) breast cancer. The study maintains Institutional Review 
Board approval at the University of North Carolina.
Histologic subtype
Histologic subtype for CBCS1–3 was determined via centralized pathologist review. Tumors 
classified as ductal, lobular, and mixed ductal-lobular comprise 84% of all CBCS1–3 cases 
with histologic subtype available. Ductal or lobular histologic subtypes tumors were defined 
as at least 80% representative of that histology. Mixed tumors contained ≥20% of one 
histologic subtype and <80% of the second histologic subtype. The following histologic 
subtypes were excluded: mixed ductal/non-lobular (n=285), mucinous (n=89), mixed ductal/
metaplastic (n=63), metaplastic (n=44), DCIS w/focal invasion (n=44), undifferentiated high 
grade (n=29), tubular (n=23), micropapillary (n=21), papillary (n=19), medullary (n=18), 
pleomorphic lobular (n=17), anaplastic (n=14), apocrine (n=11), cribriform (n=9), 
neuroendocrine (n=3), and others (n=15). Cases with unknown (n=99) or missing (n=376) 
were also excluded.
Immunohistochemistry (IHC)-based clinical breast cancer subtypes
For CBCS1–2, estrogen receptor (ER) and progesterone receptor (PR) status was abstracted 
from medical records for 80% of cases. The remaining 20% of cases with tumor tissue 
available had ER and PR status determined using IHC, which was performed at UNC. For 
tissue that was stained at UNC, a study pathologist determined ER and PR positivity using 
contemporaneous clinical cut points [9]. HER2 staining was performed at UNC for all 
CBCS1–2 cases with available tissue as described previously. HER2 positivity was defined 
as in ≥10% of tumor cells displaying weak or greater intensity of membrane/membrane plus 
cytoplasmic staining [9].
In CBCS3, 98% of cases had ER, PR, and HER2 information in their medical records. For 
the remaining 2% of cases without medical record ER, PR, and HER2 data, IHC data was 
used. IHC staining was performed at UNC with positivity cut points of ≥10% for ER and PR 
status. HER2 positivity was defined as 3+ staining intensity [negativity was defined as 0/1+ 
(equivocal cases with 2+ staining were excluded)], as described in Allott et al. (2016) [33].
For CBCS1–3, 3-marker clinical subtypes were defined as follows: Luminal A (ER+ or PR+ 
and HER2−), Luminal B (ER+ or PR+ and HER2+), Triple Negative (TN) (ER− and PR− 
and HER2−), and HER2+ (ER− and PR− and HER2+).
Statistical analyses
Patient characteristics—The associations between histologic subtype and race, age, 
menopausal status, and clinical subtype were estimated using generalized linear models that 
were adjusted for age, race, and study phase (1, 2, 3) [34]. Relative frequency differences 
(RFDs), interpretable as the percentage difference between index and referent groups, and 
95% confidence intervals (95% CIs) were estimated as the measure of association [34]. To 
account for the CBCS sampling design, weighted percentages are presented alongside 
unweighted sample size counts. Patient characteristics were defined as: race [self-report: 
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black, non-black (>98% white, henceforth referred to as white)], age (years) (<40, 40–49, 
50–59, ≥60), menopausal status (pre-, post-), and clinical subtype as defined above.
Reproductive risk factor analyses—The association between each reproductive breast 
cancer risk factor and histologic subtype was estimated in case-control (CBCS1–2) and case-
case (CBCS1–3) analyses. Polytomous logistic regression was used to obtain odds ratios 
(ORs) and 95% confidence intervals (95% CIs) as the measure of association. The following 
risk factors were studied in association with histologic breast cancer subtype: parity 
(nulliparous, 1, 2, ≥3), years since last birth (defined as: age at diagnosis/enrollment minus 
age at last birth; among parous women only) (0–≤10, 10–≤20, >20), age at first live birth 
(years) (parous women only) (<26, ≥26), lifetime lactation duration (months) (parous 
women only) (never, 0–≤12, >12), oral contraceptive use (never, former, current), and 
hormone therapy (HT) use [never, estrogen alone, combined estrogen + progesterone (E+P)]. 
Additional variables used in case-control analyses included: study phase (1, 2, 3), age 
continuous (20–74), family history of breast cancer (yes, no), alcohol intake (ever, never), 
smoking duration (years) (never, <10, 11–19, ≥20), oral contraceptive use (ever, never), 
breastfeeding (ever, never) and age at menarche (years) (<13, ≥13), and the offset term to 
account for the sampling design of CBCS. Case-case analyses are presented for CBCS1–3 to 
assess etiologic heterogeneity by histologic subtype [6, 35]. In case-case analyses, ductal 
served as the referent group compared to lobular and mixed. Case-case models are adjusted 
for age, race, and study phase.
We tested the null hypothesis that the slope of the line equals zero for age at diagnosis, 
parity, and lactation duration, each modeled as continuous variables. We conducted a race-
stratified sensitivity analysis of the risk factor-histologic subtype associations, but we were 
unable to assess racial differences in oral contraceptive and HT use due to low sample size 
among black women for current OC use and combined E+P use. All analyses were done in 
SAS version 9.4 (SAS Institute, Cary, NC). P-values were produced for a two-sided test with 
an alpha of 0.05 for statistical significance.
RESULTS
Women from the Carolina Breast Cancer Study Phases 1–3, displayed patterns consistent 
with established histological associations by age, race, menopausal status, and clinical 
subtype (Table 1). Relative to ductal histologic subtype, lobular, and mixed tumors 
(Supplemental Table 1) were less frequent among young women and black women, and in 
age-, race-, and study phase-adjusted analysis, lobular and mixed tumors were more frequent 
among premenopausal women. As other studies have shown, lobular and mixed tumors were 
predominantly Luminal A clinical subtype (ER+ or PR+/HER2−) (lobular 88.8%, mixed 
83.1%); whereas ductal tumors are less frequently Luminal A (57.9%) subtype. After 
adjusting for age, race, and study phase, associations with molecular subtype were 
statistically significant, with lobular tumors significantly more likely to be Luminal A 
clinical subtype [Relative Frequency Difference (RFD), or percent difference, compared to 
ductal: 26.3%, 95% CI (24.0, 28.5)].
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We observed unique risk factor patterns for lobular tumors relative to ductal tumors (Table 
2). Ductal tumors were inversely associated with parity, increasing lactation duration, and 
estrogen-only hormone therapy (HT) use. Among lobular tumors, parity was inversely 
associated with having 1 child versus being nulliparous, but the association was attenuated 
as parity increased. We observed a positive association between age ≥26 years at first birth 
and lobular disease [Lobular OR: 1.32; 95% CI (0.86–2.03)] and a null effect for ductal 
tumors [Ductal OR: 0.94; 95% CI (0.77–1.16)]. Lifetime lactation duration >12 months was 
positively associated with lobular disease [Lobular OR: 1.62; 95% CI (0.99–2.67)] and 
reduced for ductal disease [Ductal OR: 0.78, 95% CI (0.60–1.02)]. Former oral 
contraceptive (OC) use was associated with lobular disease [Lobular OR: 1.43, 95% CI 
(0.92–2.22)] but not ductal disease [Ductal OR: 0.96, 95% CI (0.79–1.71)]. Associations 
with hormone therapy use were stronger for lobular disease than ductal disease, with both 
estrogen alone and having a larger inverse association with lobular disease [OR: 0.59, 95% 
CI (0.33–1.06)] and combined estrogen plus progesterone (E+P) hormone therapy (HT) use 
having a larger positive association with lobular disease [OR: 1.74, 95% CI (0.99–3.06)].
To assess whether these risk factor patterns were indicative of significant etiologic 
differences between ductal (referent) and lobular disease, we conducted case-case analyses. 
Case-case analyses showed a statistically significant difference in the associations between 
lobular and ductal disease for age ≥26 years at first birth [OR: 1.35, 95% CI (1.03–1.78)], 
lifetime lactation duration >12 months [OR: 1.86, 95% CI (1.33–2.60)], and current OC use 
[OR: 1.86, 95% CI (1.08–3.20)]. These associations did not appear to differ by race (all p-
values for heterogeneity >0.50) (Supplemental Table 2). We also observed that associations 
for mixed tumors were typically intermediate in magnitude, between the estimates for 
lobular and ductal disease (Supplemental Table 3).
To address our main research question of whether risk factor-histologic subtype associations 
were independent of molecular breast cancer subtype, which is not evenly distributed by 
histologic subtype, we tested whether etiologic associations for lobular disease persisted 
after restricting to Luminal A subtype. After restricting to Luminal A clinical subtype, 
associations for lobular disease relative to ductal were similar in direction and magnitude 
particularly for age at first birth ≥26 years [OR: 1.26, 95% CI: 0.82–1.93)], lactation 
duration >12 months [OR: 1.51, 95% CI (1.02–2.25)], and oral contraceptive use [current 
OR: 1.82, 95% CI (0.99–3.36); former OR: 1.48, 95% CI (1.06–2.06)].
DISCUSSION
In the Carolina Breast Cancer Study, we observed differences in reproductive risk factor 
profiles between ductal and lobular invasive breast cancers. Lobular disease was 
consistently, positively associated with more than 10 and up to 20 years since last birth, 
older age (≥26 years) at first birth, lactation duration greater than 12 months, oral 
contraceptive use, and combined estrogen plus progesterone (E+P) hormone therapy (HT) 
use. These associations did not vary by race and were not altered by restriction to Luminal A 
tumors only, suggesting that histology and molecular subtype contribute to observed risk 
factor associations for breast cancer.
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In agreement with the previous literature, we found that relative to ductal cancers, lobular 
cancers were less frequent among black versus white women [36–39], less frequent among 
younger women [22, 36–38, 40–43], but more common among premenopausal women after 
controlling for age [23–25]. As has been shown previously, we observed that 88% of lobular 
tumors in our study were Luminal A subtype, which closely matches previous studies of 
lobular tumors (~80–90%, [7, 8, 11, 15, 17, 44, 45]), and is considerably higher than the 
overall prevalence of Luminal A subtype among invasive breast cancers (50%, [6, 7]). We 
also found that ductal tumors displayed diversity in clinical subtype and contained a 
majority of the TN and HER2+ tumor types, as others have reported [7–17].
Associations between histology and a number of reproductive risk factors among women 
from the CBCS were similar to associations reported elsewhere. We and others have shown 
lobular tumors are more strongly associated with older age at first birth with ORs ranging 
from 1.8–2.4 for lobular disease and 1.1–1.6 for ductal disease in other studies [18, 19, 21, 
22, 26, 28, 30]. We also observed an increased risk of lobular disease for women who 
reported using oral contraceptives. These findings are similar to a larger study by Newcomer 
et al. (2003) who included nearly 500 cases of lobular disease, and observed that for former 
versus never OC use, only lobular histology showed a positive association with OC use [21, 
46, 47]. Additionally, we observed an increased risk of lobular disease among current users 
of combined E+P HT compared to ductal disease, with similar magnitude and direction to 
previous reports [26–29].
In case-case analyses, lobular tumors were significantly associated with older age at first 
birth, lactation duration greater than 12 months, and current OC use suggesting that these 
risk factors may contribute to etiologic differences between ductal and lobular tumors. Even 
after restricting to the predominant lobular clinical subtype, Luminal A, the aforementioned 
risk factor associations persisted, which mirrors work by Kotsopoulos et al. (2010) who 
reported risk factor associations among lobular tumors persisted after restricting to ER+ and 
PR+ tumors [28]. Concerning lactation duration and risk of lobular disease, our findings 
differed from those reported previously in case-control studies where slightly inverse 
(OR=0.9) or null associations for lactation duration and lobular disease have been reported 
[18, 19, 47, 48]. We found that among parous women only, lactation duration greater than 12 
months was significantly associated with lobular disease relative to ductal, even after 
restricting to Luminal A subtype in our case-case analyses. Previous studies have included 
more women over the age of 50 and had lower proportions of women who reported never 
breastfeeding (30–40%) than was observed in our study (50%) [18, 19, 47, 48]. Generational 
differences in breastfeeding practices and geographic variation of breastfeeding 
initiation[49] may contribute to the observed differences in the literature for lactation 
duration and lobular carcinoma. Overall, our study supports different risk factor profiles 
between ductal and lobular tumors, particularly for risk factors that are thought to impact 
hormone levels.
The findings for invasive lobular carcinoma displaying consistent associations with a host of 
hormone-modulating, reproductive risk factors and independent of Luminal A subtype beg 
the question: is histologic subtype etiologic in origin or is it a result of selective pressures in 
the breast that encourage a tumor to develop into one histologic subtype over another? 
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Intrinsic breast cancer subtypes are hypothesized to be etiologic in nature with Luminal A 
and B arising from the luminal epithelial cells of the mammary gland and Basal-like and 
HER2-enriched arising from the basal cells of the mammary gland [2]. Conversely, 
histologic subtype is subjective in nature and determined by a pathologist from the visual 
appearance of the epithelial cells where ductal histology is characterized by tubules and 
solid nests of epithelial cells and lobular carcinoma is characterized by a non-cohesive 
phenotype with single-file strands of epithelial cells scattered throughout the stroma [5, 42]. 
Lobular carcinomas are characterized by down regulation of E-cadherin in >90% of cases; 
however, this can also be observed in a smaller percentage of ductal carcinomas [40]. 
Therefore, it is not clear that histologic subtype is truly etiologic in nature or if histology is a 
result of exposure to phenotype-modulating selective pressures present in breast tissue over 
the life course.
Our study should be interpreted in light of some limitations. We were unable to include rare 
histologic subtypes (e.g. medullary, papillary, metaplastic, etc.) in our analyses due to 
limited sample sizes. Because lobular tumors are predominantly Luminal A subtype, we 
were unable to study differences in risk factor profiles between lobular tumors that were of 
Triple Negative or HER2+ subtype. We, like other studies of histology, acknowledge some 
uncertainty around histologic classification. Interobserver reliability for histologic subtype is 
reported to be around 80% [50], possibly leading to some instability in associations across 
studies. We sought to eliminate this problem by using centralized pathology review to 
classify CBCS invasive breast tumors into histologic subtypes, by focusing on tumors that 
had a dominant ductal or lobular phenotype (at least 80% ductal or lobular), and by 
considering mixed ductal-lobular tumors separately. This may have impacted our power, 
though, and TCGA found that molecularly, mixed tumors were not a distinct disease and 
displayed genomic features that would classify them as ductal- or lobular-like [8]. Therefore, 
applying these molecular classifications to mixed ductal-lobular tumors in epidemiologic 
studies may be a step toward better characterizing risk factor profiles for mixed tumors.
To conclude, we observed differences in risk factor profiles between ductal and lobular 
tumors in the Carolina Breast Cancer Study that persisted after restricting to Luminal A 
subtype. Using both case-control and case-case analyses, we found that lobular tumors have 
unique risk factor profiles from ductal tumors when considering older age at first birth, 
increasing lactation duration, current oral contraceptive use, and combined E+P HT use. 
When we restricted to Luminal A subtype, we found that the observed reproductive risk 
factor-histologic subtype associations were not altered. Overall, our findings suggest 
potential etiologic or phenotype-modulating differences between ductal and lobular disease 
that are not driven by intrinsic subtype alone. Our findings strengthen the evidence that 
lobular tumors are sensitive to hormone-modulating exposures.
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Table 1
Relative Frequency Differences (RFD) and 95% Confidence Intervals (95% CI) for the association between 
race, age at diagnosis, menopausal status, and clinical subtype comparing lobular to ductal histologic subtype 
breast tumors (CBCS 1–3)
Ductal Lobular
Risk factor N (%*) N (%*) RFD (95% CI) p-value
Age at diagnosisa
  ≥60 697 (37.4) 109 (46.1) Ref
  50–59 591 (28.1) 65 (27.6) −2.5 (−4.3, −0.7) <0.01
  40–49 1,105 (24.7) 131 (23.0) −2.9 (−4.7, −0.2) <0.01
  <40 463 (9.8) 21 (3.3) −8.8 (−10.8, −6.8) <0.01
Raceb
  White 1,463 (76.7) 200 (83.9) Ref
  Black 1,393 (23.3) 126 (16.1) −3.5 (−5.0, −2.0) <0.01
Menopausal Statusc
  Pre 1,400 (33.2) 141 (26.9) 2.0 (0.0, 4.0) 0.05
  Post 1,456 (66.8) 185 (73.1) Ref
Clinical Subtypec,d
Luminal A 1382 (57.9) 270 (88.8) 26.3 (24.0, 28.5) <0.01
Non-Luminal A 1302 (41.3) 36 (11.2) Ref.
  Luminal B 282 (10.3) 16 (6.3)
  HER2+ 193 (6.3) 4 (0.7)
  Triple Negative 827 (25.5) 16 (4.2)
  Missing 172 20
*
Percentages weighted for sampling fractions.
a
Adjusted for race (white, black) and study phase (1, 2, 3).
b
Adjusted for age (continuous) and study phase.
c
Adjusted for age, race, and study
d
Luminal A (ER+ or PR+/HER2−); Non-Luminal A [Luminal B (ER+ or PR+/HER2+), Triple Negative (ER−/PR−/HER2−), HER2+ (ER−/PR−/
HER2+)]
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